Core Viewpoint - China National Pharmaceutical Group Co., Ltd. (China Biopharmaceutical) announced a total acquisition of Hangzhou Hejiya Biopharmaceutical Co., Ltd. for RMB 1.2 billion, aiming to enhance its capabilities in the small interfering RNA (siRNA) drug development sector [1][2]. Group 1: Acquisition Details - The acquisition price for Hejiya Biopharmaceutical is set at RMB 1.2 billion [1]. - Hejiya Biopharmaceutical specializes in the research and development of innovative siRNA drugs, focusing on significant clinical value in the treatment of metabolic diseases, cardiovascular diseases, and neurological disorders [1]. Group 2: Strategic Importance - The acquisition is expected to strengthen China Biopharmaceutical's core competitiveness in the siRNA field and expand its presence in the global market for chronic disease treatment, which is valued in the trillions [2]. - The merger will leverage the existing clinical development and commercial expansion experience of China Biopharmaceutical, providing strong momentum for sustainable growth and long-term value creation for shareholders [2]. Group 3: Innovation and Future Prospects - Hejiya has successfully overcome delivery technology bottlenecks for siRNA drugs across multiple tissues, achieving long-lasting gene silencing effects with a single administration [1]. - The collaboration is anticipated to accelerate drug development processes and expand the application of siRNA technology to address unmet medical needs in various disease areas [2].

Core Viewpoint - China National Pharmaceutical Group announced the acquisition of Hejia, expanding its presence in the siRNA sector, with a maximum base price of RMB 1.2 billion [1][3][10]. Company Overview - Hejia is a pioneering biopharmaceutical company focused on the research and development of small interfering RNA (siRNA) innovative drugs, with a comprehensive drug development system from target discovery to clinical proof of concept [3][10]. - The company targets chronic diseases in three main areas: weight loss metabolism, cardiovascular, and neurological systems [3][10]. Market Potential - The global transaction volume in the siRNA field is expected to exceed USD 35 billion by 2025, with a year-on-year growth rate of over 40% [11]. - The acquisition aims to build a next-generation cardiovascular treatment product line and enhance the metabolic field, expanding into the trillion-dollar chronic disease management market [11]. Technological Advancements - Hejia has developed a differentiated delivery platform covering multiple tissues, with proprietary intellectual property [4][11]. - The core platform, MVIP (Multivalent Import Platform), is the first clinically validated liver-targeted delivery platform capable of achieving "one injection per year" for chronic disease treatment, addressing adherence issues [11][12]. - DDP (Dual Delivery System) technology overcomes the industry challenge of dual-target efficacy, applicable to various tissues, and aims to address complex or refractory diseases [12]. - The NSDP (Neuro System Delivery Platform) targets the central nervous system and aims for a "one injection per year" delivery frequency [12].